Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.
CagriSema showed larger metabolic improvements than comparators, though variable study results mean benefits may differ across individuals.
A meta-analysis of eight randomized trials found larger metabolic improvements with CagriSema than with several active or placebo comparators. High between-study heterogeneity limits certainty about the precise effect size.
What the study was
- Study design
- Systematic review and pairwise meta-analysis of randomized controlled trials
- Population
- Adults with overweight or obesity, including participants with type 2 diabetes
- Sample size
- 6898
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes, metabolic syndrome and obesity : targets and therapy
Why it surfaced
The randomized-trial meta-analysis addresses a large cardiometabolic population and reports clinically relevant outcomes, with heterogeneity tempering confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.